Product Images Pregabalin

This is a description of the medication Pregabalin, which is a capsule with a strength of 150 mg. The quantity is 60 capsules, and the medication's NDC number is 70518-2668-01, with a source NDC of 59762-1351-01. The medication was manufactured by Greenstone LLC in Peapack, NJ 07977, with lot and expiry dates not available. The medication should be kept out of the reach of children and stored at 20-26°C (63-77°F), with excursions permitted to 15-30°C (59-86°F) [See USP]. Additionally, the medication should be used according to the package insert, and it has been repackaged by RemedyRepack Inc in Indiana, PA 15701.*

Pregabalin is a medication in capsule form, with a strength of 150mg. This package contains 90 capsules and has an NDC number of 70518-2668-00. The LOT number and expiration date is not provided. It is manufactured by Greenstone LLC. in Peapack, NJ. The medication should be kept out of reach of children and direction for use should be consulted on the package insert. It should be stored between 20-26°C (63-77°F) with permitted excursions between 15-30°C (59-86°F) as per USP guidelines. The medication has been repackaged by RemedyRepack Inc., based in Indiana, PA.*

The given text seems to be a medical report including serum creatinine levels. However, the has resulted in random characters, making it difficult to understand the context. The text is not readable and therefore, the description cannot be generated.*

The text shows a chart indicating the percent of patients improved and the percent improvement in pain from baseline. There are values under the headings "Percent of Patients Improved" and "Percent Improvement in Pain from Baseline." The values seem to indicate different treatment options and their effectiveness. However, some characters are not recognized, making it difficult to interpret the data.*

The text describes a chart or table showing the percentage of patients improved after taking Pregabalin at a dosage of 106 mg three times a day. It also includes a section showing the percentage improvement in pain from baseline. However, the formatting of the text is not clear and some of the characters are unreadable, making it difficult to provide a complete and accurate description.*

The text is reporting statistical data about the percentage of patients experiencing improvement in pain while taking different doses of Pregabalin and a placebo. The data is presented in a table format with different doses and frequency of administration. The text also includes a chart showing the percentage improvement in pain from baseline for each treatment.*

This is a table showing the percentages of patients improved with different treatments. The treatments are Pregabalin 200mg three times a day, Pregabalin 100mg three times a day and Placebo. The numbers correspond to the percentage of patients improved for each treatment at different time points. The last row shows the percentage improvement in pain from baseline for each treatment.*

This document appears to be a chart or graph showing the percent of patients that improved with different dosages of Pregabalin and a placebo. The chart includes varying numeric values, but no further context or explanation is provided.*

This is a table displaying the responder rate (%) for different treatments including a placebo at different doses measured by the number of patients who showed a specific response. The percentages for responder rates are 40.6%, 29.1%, and 22.6% for treatments with dosages of 2.5 mg/kg/day, 10 mg/kg/day, and placebo, respectively. The numbers at the bottom are the total number of patients included in the study for each treatment.*

The text describes a chart showing the percent of patients improved using different daily doses of pregabalin for pain management. It shows that the 600mg daily dose had the highest percentage of improvement, followed by the 450mg and 300mg daily doses. The chart also includes a placebo group with lower improvement percentages. The chart also displays the percentage improvement in pain from baseline for each group.*

This is a graph showing the estimated percentage of subjects without LTR (likely to respond) for a placebo group and a group that received Pregabalin over a period of 180 days. The graph shows the percentages at different intervals: 0%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, and 100%.*

This is a table that shows the percentage of subjects improved between Pregabalin and Placebo at week 12. The table also shows the number of subjects in each category.*